Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226726 · ClinicalTrials.gov registry record · Phase 1
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
A Phase 1 study of Congenital Myasthenic Syndrome, sponsored by The Foundation for Orthopaedics and Regenerative Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT07226726 is a Phase 1 study of Congenital Myasthenic Syndrome that is actively recruiting participants, run by The Foundation for Orthopaedics and Regenerative Medicine. The registered enrollment target is 20 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07226726, a Phase 1 study of Congenital Myasthenic Syndrome, is actively recruiting participants, sponsored by The Foundation for Orthopaedics and Regenerative Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Conditions Studied
Interventions
- BIOLOGICAL AlloEx exosomes
Study Locations (3)
Florida
- Prodromos Stem Cell Institute - Naples
Texas
- Prodromos Stem Cell Institute - Irving
Other
- Medical Surgical Associates Center - St John's
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226726
The ClinicalTrials.gov registry entry for NCT07226726 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Foundation for Orthopaedics and Regenerative Medicine, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Myasthenic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which AlloEx exosomes is the first listed.
NCT07226726 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07226726 about?
NCT07226726 is a clinical study titled "Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution". Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
What is the current status of trial NCT07226726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-01-01. Estimated completion is 2028-12-31.
What conditions does trial NCT07226726 study?
This clinical trial studies the following conditions: Congenital Myasthenic Syndrome.
What interventions are being tested in trial NCT07226726?
The interventions under investigation include: AlloEx exosomes (BIOLOGICAL).
Who is sponsoring clinical trial NCT07226726?
This trial is sponsored by The Foundation for Orthopaedics and Regenerative Medicine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226726 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Myasthenic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.